Last updated: September 5, 2026
Verteporfin is a mature ophthalmology drug marketed as Visudyne for photodynamic therapy. Its commercial peak occurred before anti-VEGF therapy became the standard treatment for neovascular age-related macular degeneration. Current demand is concentrated in selected retinal diseases, combination treatment protocols, and markets where photodynamic therapy remains clinically useful. Bausch + Lomb holds the commercial rights in major markets, but does not separately disclose Visudyne revenue.
Verteporfin has limited remaining traditional exclusivity value. Its principal commercial risk is therapeutic substitution by anti-VEGF injections, not imminent patent expiry. Its main opportunity is continued use in polypoidal choroidal vasculopathy, chronic central serous chorioretinopathy, and other retinal conditions where vascular occlusion from photodynamic therapy can complement or reduce injection burden.
What is verteporfin and how is Visudyne used?
Verteporfin is a benzoporphyrin derivative administered intravenously before laser activation. The drug accumulates in abnormal ocular vasculature. Nonthermal laser exposure activates verteporfin and produces localized photochemical damage, reducing blood flow through abnormal choroidal vessels.
Visudyne is approved in the United States for photodynamic therapy of predominantly classic subfoveal choroidal neovascularization associated with:
- Neovascular age-related macular degeneration
- Pathologic myopia
- Presumed ocular histoplasmosis
The FDA-approved regimen uses an intravenous infusion followed by laser treatment at a defined wavelength and dose. The product is supplied as a sterile lyophilized powder for reconstitution, making manufacturing, cold-chain handling, infusion logistics, and access to a compatible laser system part of the commercial model.[1]
What diseases are treated with verteporfin off label?
Ophthalmologists also use verteporfin in selected patients with:
- Polypoidal choroidal vasculopathy
- Chronic central serous chorioretinopathy
- Choroidal hemangioma
- Refractory choroidal neovascularization
- Some retinal vascular disorders
Use in central serous chorioretinopathy and polypoidal disease is supported by clinical literature but does not create a new FDA-approved indication. Off-label utilization can expand demand without changing the product’s regulatory label, although reimbursement and institutional protocols vary by jurisdiction.
When did verteporfin lose market exclusivity?
Verteporfin’s core patent estate is substantially expired. The original patents covering the benzoporphyrin derivative, compositions, and photodynamic treatment methods were filed in the 1990s and generally reached their term limits during the 2010s, subject to patent-term adjustments and jurisdiction-specific calculations.
| IP category |
Representative status |
Commercial effect |
| Verteporfin active compound and composition patents |
Historical patents, generally expired |
Little protection against a technically equivalent product |
| Photodynamic treatment methods |
Historical protection, generally expired |
Limited ability to block standard use |
| Visudyne formulation and manufacturing claims |
Any surviving rights require claim-level review |
May raise development barriers but are unlikely to recreate broad exclusivity |
| FDA regulatory exclusivity |
Expired |
No meaningful new-drug exclusivity remains |
| Orphan-drug exclusivity |
Not the principal commercial protection for Visudyne |
No current broad market barrier |
The relevant commercial conclusion is that verteporfin is a mature, patent-expired small molecule. Any new protection would more likely arise from a reformulated product, a novel delivery system, a new indication, or a proprietary treatment protocol than from the original active ingredient.
What is the Orange Book status of Visudyne?
Visudyne is an FDA-approved prescription drug listed in FDA drug databases. Its principal U.S. regulatory value comes from approval, manufacturing know-how, physician familiarity, and the limited number of centers equipped to perform photodynamic therapy.
The Orange Book does not provide the type of current, broad patent barrier associated with newer branded ophthalmology products. A generic applicant could theoretically pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence, and adequate manufacturing controls. The practical challenge is that verteporfin is a sterile injectable product used with a specialized administration procedure.
FDA approval would not automatically provide access to the same commercial network. A competing product would need reliable sterile manufacturing, stable supply, validated reconstitution, appropriate labeling, and distribution to retinal specialists and hospitals.
How many patents protect verteporfin?
The original verteporfin patent family included claims directed to benzoporphyrin derivatives, pharmaceutical compositions, and photodynamic treatment. Representative U.S. patent families include patents associated with benzoporphyrin derivative compounds and their use in photodynamic therapy, such as U.S. Patent No. 5,798,349 and related continuation or divisional filings.
Those patents are historical rather than current commercial barriers. Patent term generally lasts 20 years from the earliest effective nonprovisional filing date, subject to adjustments. Because the foundational filings date to the 1990s, the broad composition and method claims have reached expiration.
A complete freedom-to-operate analysis would still need to examine:
- Continuations and divisionals
- Patent-term adjustment
- Patent-term extension
- Formulation claims
- Manufacturing-process claims
- Device or laser-treatment claims
- Country-specific status
- Any later patents covering new uses
The remaining IP position is therefore best described as narrow and operational rather than exclusionary.
Who owns and markets verteporfin?
Bausch + Lomb markets Visudyne after acquiring global rights from Novartis. The transaction expanded Bausch + Lomb’s retina portfolio and gave it control of a mature product with established regulatory approvals and specialist demand.[2]
| Company |
Role |
| Bausch + Lomb |
Current commercial rights holder and marketer in major markets |
| Novartis |
Former commercial owner |
| Original research and development organizations |
Historical contributors to compound and product development |
| Retinal clinics and hospitals |
Administration sites and treatment infrastructure |
The commercial rights may differ by territory. Japan and certain other markets can have separate licensing, distribution, or regulatory arrangements. Geographic diligence should therefore distinguish global brand ownership from country-level marketing authorization and supply rights.
What is the financial trajectory of verteporfin?
Visudyne’s financial trajectory has followed the standard pattern for a first-generation specialty ophthalmology product:
- Rapid adoption after approval for neovascular AMD.
- High revenue during the period when photodynamic therapy was a principal treatment option.
- Sharp decline after anti-VEGF drugs became the dominant treatment.
- Stabilization as a niche product in selected retinal diseases.
- Continued value from an established product despite limited growth.
Visudyne became commercially important in the early 2000s. Its market weakened after the introduction of ranibizumab and widespread clinical use of bevacizumab. Aflibercept, faricimab, and treat-and-extend anti-VEGF regimens reinforced the shift toward injectable pharmacologic therapy.[3][4]
Bausch + Lomb does not report Visudyne revenue as a separate line item in its public financial reporting. The product is included within broader pharmaceutical or ophthalmology revenue categories. This prevents a precise public calculation of:
- Annual Visudyne net sales
- Gross-to-net deductions
- Regional revenue
- Product-level operating margin
- Revenue growth or decline
- Product contribution to Bausch + Lomb earnings
The product’s financial profile is likely characterized by low absolute revenue relative to Bausch + Lomb’s total business, high clinical familiarity, limited promotional requirements, and meaningful manufacturing value because sterile ophthalmic injectables can support attractive margins when competition is limited.
What factors drive verteporfin revenue?
Demand is influenced by five variables:
- Anti-VEGF treatment substitution
- Prevalence of polypoidal choroidal vasculopathy
- Adoption of reduced-fluence photodynamic therapy
- Reimbursement for off-label retinal indications
- Availability of trained physicians and laser equipment
Revenue is more sensitive to procedure volume than to broad ophthalmology prescription trends. A patient treated with verteporfin generally requires an infusion and laser procedure, unlike an office-based intravitreal injection. That limits convenience but can reduce repeated injection frequency in selected patients.
How does verteporfin compare with anti-VEGF drugs?
| Attribute |
Verteporfin |
Ranibizumab, aflibercept, faricimab |
| Administration |
Intravenous infusion plus laser activation |
Intravitreal injection |
| Primary mechanism |
Photochemical vascular occlusion |
VEGF or angiopoietin/VEGF pathway inhibition |
| Role in neovascular AMD |
Limited and selective |
Standard first-line pharmacologic treatment |
| Retreatment model |
Often procedure-based and episodic |
Repeated injections or treat-and-extend dosing |
| Equipment need |
Requires photodynamic laser platform |
Requires injection infrastructure |
| Current growth outlook |
Niche and indication-specific |
Larger and more competitive |
| Patent position |
Mature and largely expired |
Depends on product and formulation patent estate |
| Main commercial risk |
Therapeutic substitution |
Biosimilar and generic competition |
Verteporfin remains relevant where abnormal vascular anatomy responds particularly well to photodynamic therapy. Polypoidal choroidal vasculopathy is the clearest example. Combination therapy can also be used when clinicians seek greater lesion control or fewer injections.
What generic entry risks exist for Visudyne?
Generic entry is legally possible but commercially more complex than for a conventional oral tablet.
Pharmaceutical and manufacturing barriers
A competing manufacturer would need to reproduce:
- The active pharmaceutical ingredient
- Sterile injectable quality
- Lyophilized powder characteristics
- Reconstitution performance
- Stability profile
- Container-closure system
- Administration instructions
- Supply reliability
Verteporfin’s photodynamic use also creates a device and workflow dependency. A generic drug can be substitutable at the product level, but clinics still need treatment protocols, payer acceptance, and access to an appropriate laser system.
Market-entry scenarios
| Scenario |
Probability profile |
Commercial consequence |
| No approved generic |
Most favorable for incumbent pricing |
Stable niche revenue |
| One generic entrant |
Moderate price pressure |
Lower price, continued market growth in selected indications |
| Multiple sterile injectable entrants |
High price pressure |
Erosion of unit price and possible supply competition |
| New photodynamic formulation |
Potentially disruptive |
Could shift value toward improved convenience or dosing |
| New drug replacing photodynamic therapy |
Highest strategic risk |
Structural decline in verteporfin demand |
A generic entrant would probably target markets with established retinal centers rather than attempt broad primary-care distribution.
Which companies are challenging verteporfin commercially?
Competition comes less from direct verteporfin challengers than from alternative therapies.
Key competitors include:
- Regeneron and Bayer with aflibercept
- Roche with ranibizumab and faricimab
- Genentech and compounding pharmacies with bevacizumab
- Biosimilar developers targeting ranibizumab and aflibercept
- Other retinal drug developers pursuing longer-duration anti-VEGF or combination products
The competitive threat is therefore divided into two groups. Anti-VEGF products reduce the need for photodynamic therapy in AMD. Biosimilars lower the cost of injectable alternatives, which can make substitution even more attractive to payers.
What patent litigation affects verteporfin?
There is no prominent current U.S. patent litigation involving the foundational verteporfin product comparable to litigation surrounding major branded anti-VEGF products. The central patent disputes affecting verteporfin occurred during the product’s development and commercialization period rather than in the current mature-market phase.
Current legal risk is more likely to involve:
- Generic approval and product quality
- Manufacturing-process disputes
- Trademark or distribution rights
- Contractual territory restrictions
- New-use patent claims
- Reimbursement and off-label promotion issues
No major settlement agreement currently defines the U.S. generic-entry timeline for Visudyne. That is materially different from branded drugs with active Orange Book patents and Paragraph IV settlements.
What is the FDA regulatory status of verteporfin?
Visudyne remains FDA approved for its labeled ophthalmic indications. Its approval does not extend to every disease for which clinicians use verteporfin. Off-label use is lawful when prescribed by a physician, but it is not equivalent to FDA approval and may have different reimbursement treatment.
The product’s regulatory advantages are established safety data, an approved manufacturing process, and long-term clinical familiarity. Its disadvantages are an older label, limited formal expansion into newer retinal indications, and dependence on a procedure that competes with simpler injection-based treatment.
How strong is the verteporfin commercial position?
The verteporfin franchise is commercially durable but not strongly protected by patents. Its strength rests on clinical utility and market structure.
| Factor |
Assessment |
| Patent strength |
Low |
| FDA approval value |
Moderate |
| Manufacturing complexity |
Moderate to high |
| Brand recognition among retina specialists |
High |
| Exposure to anti-VEGF substitution |
High |
| Generic vulnerability |
Moderate |
| Growth potential |
Low to moderate |
| Margin durability |
Potentially favorable if supply remains limited |
| Strategic value to Bausch + Lomb |
Niche retina portfolio asset |
The strongest defense is the product’s role in particular retinal phenotypes, especially where reduced-fluence therapy or combination treatment is accepted. The weakest defense is the lack of broad exclusivity and the availability of well-established alternatives.
What licensing and partnership opportunities exist for verteporfin?
The most credible licensing opportunities involve new applications rather than the legacy product alone. Potential structures include:
- Regional commercialization rights
- New formulations with improved shelf life or administration
- Combination regimens with anti-VEGF drugs
- Photodynamic therapy platforms for nonretinal tumors
- Research licenses involving YAP/TEAD pathway inhibition
- University or biotechnology collaborations for oncology applications
Verteporfin has attracted laboratory interest as a potential inhibitor of YAP-TEAD signaling and mechanotransduction. Those findings have not converted into an FDA-approved oncology product. The commercial value of that research is therefore option value rather than current revenue.
Key Takeaways
- Verteporfin is a mature, FDA-approved ophthalmology drug marketed as Visudyne.
- Bausch + Lomb holds major commercial rights after the transfer from Novartis.
- Product-specific revenue is not publicly disclosed.
- Revenue declined sharply after anti-VEGF therapy displaced photodynamic therapy in neovascular AMD.
- Current demand is concentrated in polypoidal choroidal vasculopathy, central serous chorioretinopathy, and other selected retinal conditions.
- Foundational verteporfin patents are generally expired, leaving limited broad exclusivity.
- Generic entry is possible but constrained by sterile manufacturing, procedure requirements, and specialized retinal distribution.
- The largest commercial threat is therapeutic substitution, not patent litigation.
- The most valuable future opportunities involve new indications, combination therapy, formulation improvements, and regional licensing.
FAQs
Is verteporfin still commercially available?
Yes. Visudyne remains an FDA-approved product and is commercially supplied for photodynamic therapy in appropriate retinal conditions.
Can a generic version of Visudyne be launched?
Yes, in principle. A manufacturer would need to satisfy FDA requirements for a sterile injectable, including pharmaceutical equivalence, bioequivalence where applicable, manufacturing controls, and product stability.
Is verteporfin used to treat cancer?
Verteporfin is being studied in laboratory and early translational research involving YAP/TEAD signaling and other pathways. It is not FDA approved as an oncology treatment.
Does verteporfin have biosimilar competition?
No. Biosimilars apply to biological products. Verteporfin is a chemically synthesized small molecule, so any competing product would generally be evaluated through a generic-drug pathway rather than a biosimilar pathway.
What is the main investment risk for the Visudyne franchise?
The principal risk is continued substitution by anti-VEGF drugs and competing retinal treatment protocols. Patent expiry is already largely reflected in the product’s mature commercial status.
References
-
U.S. Food and Drug Administration. (2023). Visudyne (verteporfin for injection) prescribing information. FDA.
-
Bausch + Lomb Corporation. (2019). Bausch + Lomb acquires global rights to Visudyne from Novartis. Bausch + Lomb.
-
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., Stahl, N., Vitti, R., Berliner, A. J., Soo, Y., Anderesi, M., Groetzbach, G., Zeitz, O., Nguimfack, P., Soubrane, G., & Schmidt-Erfurth, U. (2012). Intravitreal aflibercept for diabetic macular edema. Ophthalmology, 119(12), 2537-2548.
-
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1432-1444.
-
U.S. Patent No. 5,798,349. (1999). Benzoporphyrin derivative monoacids for use in photodynamic therapy. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
